This content is intended for healthcare professionals in France, Germany, Italy and Spain.

Please confirm that you are a healthcare professional practicing in France, Germany, Italy and Spain.


This activity has been sponsored by Sanofi. Sanofi provided financial support, video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Multiple Myeloma View Time: 70 mins

touchMEETING HIGHLIGHTS A voyage of discovery: Exploring the latest evidence for 1q21+

Highlights from a sponsored symposium at the 4th European Myeloma Network Meeting, exploring data and controversies surrounding 1q21+.

  • Part 1: Meeting Presentations
Leave Feedback
Watch Time: 05:25

Dr Martin Kaiser introduces the agenda and provides an overview of 1q abnormalities in multiple myeloma.

Watch Time: 11:09

Dr Mattia D’Agostino presents the case supporting 1q21+ to be considered a high risk feature in multiple myeloma.

Watch Time: 07:13

Dr Cyrus Khandanpour argues that there is still insufficient evidence to support gain of 1q alone as a high-risk factor.

Watch Time: 05:45

Drs Martin Kaiser and Mattia D’Agostino discuss how 1q21+ plays a role in their assessment of risk in newly-diagnosed patients.

Watch Time: 05:50

Dr Mattia D’Agostino considers the utility and timing of 1q21+ testing in clinical practice.

Watch Time: 07:54

Drs Martin Kaiser and Mattia D’Agostino discuss the clinical utility of repeat FISH panel testing during the disease course for RRMM.

Watch Time: 11:10

Dr Martin Kaiser dives into the clinical data from Phase 3 trials in RRMM that evaluated outcomes according to 1q21+ status.

Watch Time: 04:18

Drs Martin Kaiser and Mattia D’Agostino discuss the treatment of 1q21+ patients at diagnosis and relapse.

Watch Time: 11:30

Drs Martin Kaiser and Mattia D’Agostino respond to questions from the symposium audience.

Leave Feedback
Overview & Learning Objectives

Highlights from a Sanofi-sponsored satellite symposium at the 4th European Myeloma Network Meeting. Three leading experts discuss the latest evidence around 1q21+ in multiple myeloma.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recognize the association between 1q21+ and poor disease outcomes in multiple myeloma.1
  • Recall guideline recommendations to test for gain of 1q at diagnosis and relapse.2-4
  • Consider how 1q21+ may influence treatment decisions for newly-diagnosed patients as well as those with relapsed or refractory multiple myeloma (RRMM).
  • Evaluate evidence from randomized clinical trials that analyzed treatment efficacy with respect to 1q21+ status.
Faculty & Disclosures
Dr Martin Kaiser

The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom

Martin Kaiser, MD, FRCP, FRCPath is a Consultant Haematologist at The Royal Marsden and a Clinical Scientist at The Institute for Cancer Research.

Dr Martin Kaiser discloses: Honoraria from: Abbvie, BMS/Celgene, Janssen, Takeda and Sanofi. Advisory fees from: Abbvie, BMS/Celgene, Janssen, Pfizer, GSK and Seattle Genetics. Research support from: BMS/Celgene and Janssen. Travel support from: Takeda, Janssen.

Dr Mattia D’Agostino

University of Turin, Turin, Italy

Mattia D’Agostino, MD, is Assistant Professor in the Myeloma Unit, Division of Haematology, at the University of Turin.

Dr Mattia D’Agostino discloses: Honoraria from: GSK, Janssen and Sanofi. Advisory fees from: BMS, GSK and Sanofi. Research support from: Janssen.

Dr Cyrus Khandanpour

University Medical Center Schleswig-Holstein, Kiel, Germany

Cyrus Khandanpour, MD, MBA, is Deputy Director of the Department of Haematology and Oncology at the University Hospital Schleswig-Holstein.

Dr Cyrus Khandanpour discloses: Honoraria from: Janssen, Sanofi, BMS, Amgen and GSK. Advisory fees from: Research support from: Janssen, Sanofi, BMS, Amgen and GSK. Research support from: Janssen, Sanofi, BMS, Amgen and GSK.


View and download resources from this activity to support your learning, or share with your HCP colleagues.

  1. Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4(15):3509-3519.
  2. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309-322.
  3. NCCN Guidelines for Multiple Myeloma V 3.2023.
  4. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-62.
Feedback Close

Please provide feedback for this touchMEETING HIGHLIGHTS on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72